This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

SO178

Modulating and enhancing piezoelectric channels through haptic technology: a nonpharmacological approach to symptom management

INFLUENCING AND ENHANCING PIEZOELECTRIC CHANNELS VIA HAPTIC TECHNOLOGY: A NONMEDICATION APPROACH FOR SYMPTOM MANAGEMENT

Topical patches delivering haptic vibratory stimuli were associated with statistically significant improvements in measures of sleep, pain, balance, and athletic performance in four randomized placebo-controlled trials.

The study evaluates whether Haptic Vibrotactile Trigger Technology (VTT) affects sleep, pain, balance, and athletic performance through PIEZO1/PIEZO2 mechanosensitive ion channels, drawing on four randomized placebo-controlled trials. In four double-blind trials, participants used either a topical patch incorporating VTT or a visually identical sham patch for 7 to 14 days, with safety and efficacy assessed using validated scales and wearable-based functional measurements; the trials comprised REM/RESTORE for sleep and insomnia (n=33), FREEDOM for pain and quality of life (n=148), LIBERTY/PROTECT for balance and falls (n=68), and VICTORY/POWER-UP for athletic performance (n=70). In the sleep trial, by day 14, PSQI scores changed from 8.5 to 2 in the active group (-5.0 points, p<0.001) and from 9 to 7 in the placebo group (-1.0 point, p=0.032); ISI scores changed from 14.5 to 3 in the active group (-9.5 points, p<0.001) and from 15 to 12 in the placebo group (0.0 points, p=0.113); sleep onset latency changed from 32.5 to 20 minutes in the active group (-15.0 minutes, p<0.001) and from 35 to 30 minutes in the placebo group (-10.0 minutes, p=0.017); more than 83% of participants in the active group reported being very or extremely satisfied (placebo: 40%). In the FREEDOM trial, significant reductions in Brief Pain Inventory severity and interference scores (p<0.05), increased range of motion and flexibility, and improvements across all quality-of-life domains were observed on day 14. In the LIBERTY trial, adults aged 55 to 85 showed a 4% reduction in classification as being at high risk of falling and significant improvements in reaction time and the time taken to stand up and sit down (p<0.05), while changes in the control group were not significant. In the VICTORY trial, NCAA Division I athletes showed increases in knee flexion strength in both legs compared with baseline at p<0.001, with gains significantly greater than those in the placebo group; the poster discloses that the studies were funded by the patch manufacturer.

All WCP 2026 summaries